Notably, this study included broad range of GLP-1 drugs, including much older GLP-1s that have far lower anti-obesity, anti-craving, and anti-addictive effects: abiglutide (Eperzan, Tanzeum), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin, Lyxumia), semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro) Its possible that the associations that were found would be even stronger if the study had looked exclusively at semaglutide and tirzepatide, which are the current best-in-class options for weight loss
DVT was not a pre-specified endpoint in SUSTAIN-6
Get the edge you need to live a lifestyle without boundaries
This helps to buy you the time and headspace to understand why your body may have struggled to lose weight previously, and to build new long-term healthy habits
Youre then routed to the cash-pay Ro Body Membership path ($149/mo, first month $39 with promo)